Every year, more men and women in the United States die from lung cancer than any other type of cancer — and more than half people diagnosed die within one year. Nearly 13 percent of new cancer diagnoses are lung cancer. But despite these facts, only nine percent of National Cancer Institute funds are used to support lung cancer research.
The Lung OncoSET is an extension of the Lurie Cancer Center's breakthrough OncoSET Precision Medicine Program. OncoSET (Sequence, Evaluate, Treat) is based on the premise that each individual and every person's cancer is unique. It harnesses the power of precision medicine to identify tailored therapies for patients based on the abnormal genes specific to their tumor.
The potential for patients with lung cancer is groundbreaking. The OncoSET Clinic's approach combines genomic sequencing and sophisticated molecular analysis with standard pathology to identify new, individually tailored treatments and clinical trials. In 2014, the Lurie Cancer Center became the first academic cancer center in Chicago and one of only a handful in the nation to provide this kind of personalized medicine to patients with tumors — especially those tumors that are resistant to traditional cancer therapies.
Join us in providing more effective, personalized treatments for patients with lung cancer — patients who currently have very limited options.
Vice President of Philanthropy
Northwestern Memorial Foundation
Read the Blog
Read Chuck Maniscalco's latest blog post to learn more about some of the work being done through the Lung OncoSET. After being diagnosed with Stage IV lung cancer in October 2016, Chuck is benefitting from the advanced, individualized and research-based treatment options we offer at the Lung OncoSET. Chuck is currently retired, after a long career in business, including President of Gatorade, CEO of Quaker, Tropicana and Gatorade, and CEO of Seventh Generation.Back to top